Eric A. Adams

ERIC A. ADAMS was appointed Chief Executive Officer, President and Director of
enGene, Inc., in March 2004. enGene Inc. is a Vancouver, British Columbia-based
biotechnology company developing an innovative therapeutic platform, called
GEMS (Gut Endocrine-cell Modification System), which is targeted to induce
normal cells in the intestinal tract to produce a wide range of therapeutic
proteins (drugs) to treat a broad spectrum of diseases including diabetes,
obesity, GI disorders and hemophilia. He has more than 20 years’ management
experience in international business development, marketing, mergers and
acquisitions and sales in the pharmaceutical and related healthcare industries.
In addition to his duties at enGene, Mr. Adams serves as a Strategic Advisor to
Augurex Life Sciences Corp. He was also a founding member and Director of
Omnitech Capital Corporation (now HealthPricer Interactive Ltd. –
HealthPricer.com) and is a member of the University of Southern Indiana-Pott
College Board of Advisors. He is a frequent guest lecturer at the SFU Management
of Technology-MBA graduate program and University of South Carolina Masters of
International Business Studies Program. Prior to enGene, Mr. Adams was a
Director of Oncology Marketing with QLT Inc. (Vancouver), Director of
International Marketing for severe burn products at Advanced Tissue Sciences,
Inc. (San Diego) and the Senior Business Development Manager for Anti-Infectives
at the International Division of Abbott Laboratories, Inc. (Chicago), where he
managed all ex-US commercial activities related to Abbott’s first $1 billion
product, clarithromycin (BIAXIN). He also worked with Fresenius AG (Germany) as
a Country Manager for the US and Italy, and as Joint Venture/Acquisition Team
Leader. He attained a Master of International Business Studies degree from the
University of South Carolina and a Bachelor’s degree in Chemistry from
University of Southern Indiana.